2021 ASH Annual Meeting

At ASH this year, we will share new data from our robust portfolio and pipeline of advanced therapeutic platforms in cancer and blood disorders, showcasing the impact of our bold science in research.

Bold Science: Transforming Lives, Striving for Cures
Reimagining Cancer and Blood Disorders

Novartis continues to pursue scientific breakthroughs with the ambition to transform lives and renew patients’ hopes for the future. Novartis products reach more than 800 million people globally and we are finding innovative ways to expand access to our medicines.

Scientific Presentations

Abstracts from our breaking clinical trials

Learn More

Pipeline

View our broad research portfolio with innovative compounds in all phases of development.

Learn More

ASH Video Collection

Videos of our key ASH presentations.

Learn More

Focus Areas

Malignant Hematology

.lazy { display: none; }

Chimeric Antigen Receptor T-Cell Therapy (CAR-T)

.lazy { display: none; }

Chronic Myeloid Leukemia (CML)

.lazy { display: none; }

Myelodysplastic Syndromes (MDS) & Acute Myeloid Leukemia (AML)

.lazy { display: none; }

Myeloproliferative Neoplasms (MPN)

Non-Malignant Hematology

.lazy { display: none; }

Immune Thrombocytopenic Purpura (ITP)

.lazy { display: none; }

Graft versus Host Disease (GvHD)

.lazy { display: none; }

Paroxysmal Nocturnal Hemoglobinuria (PNH)

.lazy { display: none; }

Sickle Cell Disease

Our 4 Bold Approaches to Cancer Treatment

Reimagining Cancer & Blood Disorders

Novartis is uniquely positioned to lead the next wave of novel investigational treatments through our strengths in 4 therapeutic platforms: targeted therapy, radioligand therapy, cell & gene therapy, and immunotherapy.

Learn More

.lazy { display: none; }

Use of website is governed by the Terms of Use and Privacy Policy.

11/21 163048

Learn About a New Treatment Option in CML

See Our Latest Research at ASH 2021

Is TIM-3 expression causing immune dysfunction in HR-MDS and AML?

2021 ASH Annual Meeting